We report 2 cases of late recurrence of osteosarcoma after 6 and 7 years. One patient had pulmonary metastasis, and the other had soft tissue recurrence. Both patients underwent complete resection and chemotherapy. The first patient achieved complete remission and remained disease-free 47 months later and had no limitation in his daily life. The second patient had a re-recurrence and underwent further resection and chemotherapy. He remained diseasefree 35 months later and could walk using a T-handled walking cane.
improvement in chemotherapy, >50% of patients with non-metastatic osteosarcoma of the extremities achieve long-term survival. [1] [2] [3] [4] [5] [6] Local recurrence usually occurs within the first 3 years, [7] [8] [9] [10] [11] although late recurrence (after 5 years) has also been reported. 12, 13 Caffeine is a xanthine that enhances the action of substances that damage cellular DNA, and may inhibit post-replication repair of sublethally damaged DNA. 14 Caffeine has a synergistic effect with anticancer drugs and enhances the action of various anticancer drugs that inhibit DNA synthesis. 15 With caffeine-potentiated chemotherapy, the 5-year survival rate in patients with non-metastatic osteosarcoma has improved to 90%. 16 We report 2 cases of late recurrence of osteosarcoma treated with caffeine-potentiated chemotherapy.
case reports

Patient 1
In June 2004, a 17-year-old man presented with pain in his right knee. Radiographs and magnetic resonance imaging (MRI) revealed a bone tumour involving the periosteum of the right proximal tibia (Fig. 1) . A biopsy revealed osteoid formation and atypical spindle cells. Metastasis was not found on full-body computed tomography (CT). The patient underwent 5 cycles of neoadjuvant caffeinepotentiated chemotherapy (cisplatin, adriamycin, and caffeine) prior to limb-salvaging surgery. Preoperative radiological evaluation indicated good response. He then underwent marginal excision and bone reconstruction using an external fixator. Histological examination revealed complete resection, as no viable tumour cells were noted in the margins, indicating grade IV/IV chemotherapeutic effect. Postoperatively, the patient underwent 3 cycles of chemotherapy (high-dose methotrexate).
Six years later, chest radiographs revealed a left pulmonary lesion, which was confirmed by CT as metastasis. Nonetheless, he had no symptoms of pain or cough. He underwent left thoracotomy with wedge resection of the metastasis. Histological examination showed complete resection. He then underwent 3 courses of caffeine-potentiated chemotherapy (ifosfamide, etoposide, and caffeine). He was followed up every 3 months for one year and every 6 months thereafter. He remained disease-free 47 months later and had no limitations in his daily life.
Patient 2
In September 2003, a 10-year-old boy presented with pain in the right hip. Radiographs and MRI revealed a bone lesion in the right proximal femur (Fig. 2) . A biopsy revealed osteoid formation and atypical spindle cells. Metastasis was not found on full-body CT. He underwent 5 cycles of neoadjuvant caffeinepotentiated chemotherapy (cisplatin, adriamycin, and caffeine) prior to limb-salvaging surgery. Preoperative radiological evaluation indicated a partial response, and he underwent wide excision and composite reconstruction using an autograft. Histological examination revealed >90% necrosis of the tumour. He then underwent 3 cycles of chemotherapy (highdose methotrexate). Seven years later, he noticed a 15-cm swelling in his right thigh, with no pain or tenderness. MRI and positron emission tomography-computed tomography (PET-CT) revealed an intramuscular tumour, which was confirmed by biopsy to be a recurrence of the soft tissue osteosarcoma. He immediately underwent wide-margin tumour resection and limb salvage surgery. Histological examination revealed complete resection of the tumour. He then underwent 3 courses of caffeinepotentiated chemotherapy (ifosfamide, etoposide, and caffeine). Eight months later, MRI revealed a local re-recurrence. He then underwent tumour resection and mega-prosthesis reconstruction, followed by 3 courses of adjuvant chemotherapy (gemcitabine and docetaxel). Nine months later, he developed lung metastasis and underwent thoracotomy with wedge resection of the metastasis. Histological examination showed complete resection. He then underwent immunotherapy, combining tumour cryogenic treatment with dendritic cells. He was followed up every 3 months for one year and every 6 months thereafter. He remained disease-free 35 months later and could walk using a T-handled walking cane.
discussion
In a study of 1703 patients with osteosarcoma followed up for a median of 3.8 years, 23 (1.4%) patients had recurrence after 5 years. 6, 11 The late recurrence rate was 2.9% (8 of 279 patients) at the Memorial Sloan-Kettering Cancer Center in New York, 9 and 2% (13 of 648 patients) at the Rizzoli Orthopedic Institute in Bologna, Italy.
17 (Table) . At our hospital, 1.8% of patients had a recurrence after >5 years; caffeine-potentiated chemotherapy achieved a 5-year survival of >90% in patients with non-metastatic osteosarcoma. 16 Improvement in chemotherapy may alter the natural course of the disease and delay recurrences. 8 The European Society for Medical Oncology suggested a 10-year follow-up for osteosarcoma patients. 18 Nonetheless, recurrences have been reported after >10 years of disease-free interval.
More than 75% of recurrences metastasise to the lung. [5] [6] [7] 9 Routine follow-up should include chest radiography in addition to radiography at primary disease sites. MRI is not suitable for detection of local recurrences owing to artefacts of the metal prosthesis for limb salvage. Bone scanning can detect local recurrence and metastasis, but uptake with aseptic loosening may cause confusion. PET-CT with full-body scanning is the investigative tool of choice, with the exception of the central nervous system.
The prognosis for patients with late recurrence is good. Patients with a disease-free interval of >2 years have a better post-recurrence survival rate than those with shorter disease-free intervals. 4 The median survival rate after recurrence was 17 (range, 2-68) months at the Meyerstein Institute of Oncology in London, 12 and 60 (range, 5-119) months at the Rizzoli Orthopaedic Institute, with 65% of patients achieving complete remission. 17 After recurrence, the effectiveness of cisplatin, adriamycin, ifosfamide, and etoposide is limited owing to drug resistance. Hence, development of new drugs is needed. Since 1998, gemcitabine has been used for treatment of sarcoma. 19 Gemcitabine is a difluorinated analogue of deoxycytidine and acts as an S-phase-specific drug that interferes with DNA chain elongation and disruption of cell growth. 20 The response rates of single-agent gemcitabine in patients with soft tissue and bone sarcomas in 5 phase 2 trials were 3%, 3%, 5.5%, 11%, and 18%, with a median of 5.5%. [21] [22] [23] [24] [25] We have used cryoimmunotherapy for treatment of bone and soft tissue sarcomas since 2008. 26 Combining tumour cryotreatment with dendritic cell therapy promotes tumour-specific immune responses and enhances systemic immune responses.
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